Key points are not available for this paper at this time.
In recent decades, there has been a significant increase in the frequency of immune-related adverse event (irAE)–associated renal injury due to the dramatic advances of anti-cancer immunotherapy. Of these, the most popular renal lesion is irAE-associated tubulointerstitial nephritis (irAE-TIN). Since the COVID-19 pandemic, we also often experience cases with
Fujomoto et al. (Mon,) studied this question.